November 09, 2015.
AstraZeneca has agreed to acquire ZS Pharma for $2.7 billion.
ZS Pharma’s leading product candidate is ZS-9, an investigational molecule for the treatment of high levels of potassium in the blood, or hyperkalemia. ZS-9 is believed to work by mimicking the function of physiological ion channels in cells.
Upon deal completion, AstraZeneca will wholly own ZS Pharma, which has approximately 200 employees. ZS Pharma’s board of directors has unanimously approved the terms of the agreement.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.